Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 5, 2013, Pages 918-926

  Porcelli, L ^a   Quatrale, A E ^a   Mantuano, P ^a   Silvestris, N ^a   Rolland, J F ^a   Biancolillo, L ^a   Paradiso, A ^a   Azzariti, A ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Biomarkers; Clinical trials; Combination therapy; EGFR; mTOR

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; K RAS PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; NERATINIB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TEMSIROLIMUS; XL 765;

ACIDOSIS; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMATITIS; TRIPLE NEGATIVE BREAST CANCER;

EID: 84876706418     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804547295     Document Type: Article

References (93)

1. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. ProcNatlAcadSci USA 2005; 102(10): 3788-93.
2. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFRtargeted therapies. Expert OpinTherTargets 2009; 13(3): 339-62.
3. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827): 1039-43.
4. Stommel JM, Kimmelman AC, Ying H, Dennis PA. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318(5848): 287-90.
5. LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11(1-2): 32-50.
6. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5(8): 671-88.
7. Abraham RT, Eng CH. Mammalian target of rapamycin as a therapeutic target in oncology. Expert OpinTher Targets 2008; 12(2): 209-22.
8. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66(3): 1500-8.
9. Rodon J, Perez J, Kurzrock R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist 2010; 15(1): 37-50.
10. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10(5): 307-18.
11. Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010; 39(2): 171-83.
12. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrientsensitive complex that signals to the cell growth machinery. Cell 2002; 110(2): 163-75.
13. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. CurrBiol 2004; 14(14): 1296-302.
14. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12(1): 9-22.
15. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007; 17(8): 666-81.
16. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137(5): 873-86.
17. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009; 37(1): 217-22.
18. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8(8): 627-44.
19. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010; 29(26): 3733-44.
20. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307(5712): 1098-101.
21. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-typespecific repression of mRNA translation. ProcNatlAcadSci USA 2008; 105(45): 17414-9.
22. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J BiolChem 2009; 284(12): 8023-32.
23. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoSBiol 2009; 7(2): e38.
24. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1Rdependent mechanism. Oncogene 2007; 26(13): 1932-40.
25. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest 2008; 118(9): 3065-74.
26. Garcia-Martinez JM, Moran J, Clarke RG, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009; 421(1): 29-42.
27. Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69(15): 6232-40.
28. Zhang YJ, Duan Y, Zheng XF. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 2011; 16(7-8): 325-31.
29. Takeuchi H, Kondo Y, Fujiwara K, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005; 65(8): 3336-46.
30. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8(3): 179-83.
31. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther; 4(1): 101-12.
32. Rao RD, Mladek AC, Lamont JD, et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005; 7(10): 921-9.
33. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9(8): 550-62.
34. Schmid K, Bago-Horvath Z, Berger W, et al. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 2010; 103(5): 622-8.
35. Jimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007; 96(6): 952-9.
36. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16(4): 525-37.
37. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003; 4(5): 343-8.
38. Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. BiochemPharmacol 2008; 75(5): 1035-44.
39. Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008; 98(5): 923-30.
40. Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J ClinOncol 2010; 28(29): 4425-33.
41. Herberger B, Berger W, Puhalla H, et al. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol Cancer Ther 2009; 8(6): 1547-56.
42. Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in nonsmall-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5(11): 2676-84.
43. Liu T, Yacoub R, Taliaferro-Smith LD, et al. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther 2011; 10(8): 1460-9.
44. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005; 65(23): 10992-1000.
45. Miled N, Yan Y, Hon WC, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007; 317(5835): 239-42.
46. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVPBEZ235. Cancer Res 2008; 68(22): 9221-30.
47. Santiskulvong C, Konecny GE, Fekete M, et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011; 17(8): 2373-84.
48. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. MolCancerTher 2008; 7(7): 1851-63.
49. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68(19): 8022-30.
50. Lin X, Bohle AS, Dohrmann P, et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001; 386(4): 293-301.
51. Zito CR, Jilaveanu LB, Anagnostou V, et al. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 2012; 7(2): e31331.
52. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6(3): 184-92.
53. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95(1): 29-39.
54. Stokoe D, Stephens LR, Copeland T, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997; 277(5325): n567-70.
55. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22(18): 2812-22.
56. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res 2003; 9(12): 4340-6.
57. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. ProcNatlAcadSci USA 2001; 98(18): 10314-9.
58. Fan QW, Cheng CK, Nicolaides TP, et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007; 67(17): 7960-5.
59. Wang MY, Lu KV, Zhu S, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006; 66(16): 7864-9.
60. Li T, Yang Y, Li X, Xu C, Meng L. EGFR-and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells. Mol Cell Biochem 2012; 361(1-2): 19-29.
61. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120(8): 2858-66.
62. Chu C, Noel-Hudson MS, Boige V, et al. Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. FundamClinPharmacol 2012 [Epub ahead of print].
63. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001; 4(6): 378-91.
64. Dennis PB, Pullen N, Kozma SC, Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 1996; 16(11): 6242-51.
65. Dilling MB, Germain GS, Dudkin L, et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol-Chem 2002; 277(16): 13907-17.
66. Bergsland EK, Watt L, Ko AH, et al. A phase II study to evaluate the safety and efficacy of RAD001 plus erlotinib in patients with well-differentiated neuroendocrine tumors (NET). J ClinOncol 2012; 13(2): 169-73.
67. Davies JM, Raftery LL, Sanoff HK, et al. Phase I study of the combination of everolimus (RAD001) with panitumumab in patients with refractory solid malignancies. J Clin Oncol 2010; 28 (15 Supple13085).
68. Cohen RB, Janne PA, Engelman JA, et al. A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J ClinOncol 2010; 28 (15 Suppl3015).
69. Flaig TW, Costa L, Breaker K, et al. Erlotinib with sirolimus for advanced renal cell carcinoma: Preliminary efficacy results. ASCO Genitourinary Cancers Symposium 2009; abstract 327.
70. Chang KJ, Fisher W, Kenady D, et al. Multicenter randomized controlled phase III clinical trial using TNFerade (TNF) with chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC): Interim analysis (IA) of overall survival (OS). J ClinOncol 2009; 27(15 Suppl4605).
71. Mayer IA, Means-Powell J, Shyr Y, et al. A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer. Cancer Res 2009; 69(24 Suppl 3).
72. Phuphanich S, Rudnick J, Chu R, et al. A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastomamultiforme (GBM). J ClinOncol 2008; 26(abstract 2088).
73. Robins HI, Wen PY, Chang SM, et al. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J ClinOncol 2007; 25(18 Suppl).
74. Avadhani AN, Flaherty K, Rosen M, et al. A phase I trial of RAD001 in combination with cetuximab in patients with advanced solid tumors. J ClinOncol ASCO Annual Meeting Proceedings 2007; 25(18 Suppl).
75. Kris MG, Riely GJ, Azzoli CG, et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial. J ClinOncol ASCO Annual Meeting Proceedings 2007; 25(18 Suppl): 7575.
76. Nguyen TD, Lassman AB, Lis E, et al. A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastomamultiforme (GBM). J ClinOncol ASCO Annual Meeting Proceedings 2006; 24(18 Suppl).
77. Papadimitrakopoulou V, Blumenschein G, Rollins M, et al. A phase I/II study investigating the combination of RAD001(R) (everolimus) and erlotinib (E) as 2nd /3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. J ClinOncol ASCO Annual Meeting Proceedings 2006; 24(18 Suppl).
78. Shaffer DR, Abrey L, Beekman K, et al. A phase I/II trial of RAD 001 with gefitinib in patients with castrate metastatic prostate cancer and glioblastomamultiforme. J ClinOncol ASCO Annual Meeting Proceedings 2006; 24(18 Suppl).
79. Milton DT, Kris MG, Azzoli CG, et al. Phase I/II Trial of Gefitinib and RAD001 (Everolimus) in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC). J ClinOncol ASCO Annual Meeting Proceedings 2005; 23(16 Suppl).
80. Rich JN, Reardon DA, Quinn JA, et al. A phase I trial of gefitinib (Iressa; ZD1839) plus rapamycin for patients with recurrent malignant glioma. J ClinOncol ASCO Annual Meeting Proceedings 2005; 23(16 Suppl).
81. Das A, Badruddoja M, Tryciecky D, et al. Phase I study of gefitinib and rapamycin in patients with recurrent or progressive glioblastoma (Gbm). J ClinOncol ASCO Annual Meeting Proceedings 2005; 23 (16 Suppl).
82. Milton DT, Riely GJ, Azzoli CG, et al. Phase 1 trial of everolimus and gefitinib in patients with advanced non small-cell lung cancer. Cancer 2007; 110(3): 599-605.
83. Kreisl TN, Lassman AB, Mischel PS, et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 2009; 92(1).
84. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 2010; 96(2).
85. Azzariti A, Porcelli L, Simone GM, et al. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer ChemotherPharmacol 2010 Jan; 65(2): 335-46.
86. Bryce AH, Rao R, Sarkaria J, et al. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs 2011 [Epub ahead of print].
87. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drugresistant mutants of ABL, KIT, and EGF receptor kinases. ProcNatlAcadSci USA 2005 Aug 2; 102(31): 11011-6.
88. website: http: //clinicaltrials.gov/ct2/show/NCT00838539
89. website: http: //clinicaltrials.gov/ct2/show/NCT00352443
90. website: http: //clinicaltrials.gov/ct2/show/NCT01111825
91. website: http: //clinicaltrials.gov/ct2/show/NCT01272141
92. website: http: //clinicaltrials.gov/ct2/show/NCT00353301
93. website: http: //clinicaltrials.gov/ct2/show/NCT01009203